The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum–DNA binding
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., & Fojo, T. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)81490-6 · Cited by 615
Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y.-P., Uetake, H., Danenberg, K. D., Groshen, S., Tsao-Wei, D. D., Danenberg, P. V., & Lenz, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4298 · Cited by 610
Is Cisplatin-Induced Cell Death Always Produced by Apoptosis?
Gonzalez, V. M., Fuertes, M. A., Alonso, C., & Perez, J. M. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)09232-0 · Cited by 578
Eastman, A. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90009-x · Cited by 539
Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond, É., Faivre, S. J., WOYNAROWSKI, J. M., & Chaney, S. G. (1998) · PubMed · Cited by 520
Cellular and molecular pharmacology of oxaliplatin.
Raymond, É., Faivre, S. J., Chaney, S. G., WOYNAROWSKI, J. M., & Cvitkovic, E. (2002) · PubMed · Cited by 463
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
Reed, E. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90056-1 · Cited by 397
Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions
Gamelin, L., Boisdron‐Celle, M., Delva, R., Guerin‐Meyer, V., Ifrah, N., Morel, A., & Gamelin, E. C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0666 · Cited by 346
Grolleau, F., Gamelin, L., Boisdron-Celle, M., Lapied, B., Pelhate, M., & Gamelin, E. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.85.5.2293 · Cited by 344
Gamelin, E., Gamelin, L., Bossi, L., & Quasthoff, S. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.35525 · Cited by 321
Oxaliplatin-related side effects: Characteristics and management
Cassidy, J., & Misset, J.-L. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)90016-3 · Cited by 298
Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C., Hamilton, T. C., & Chaney, S. G. (1998) · PubMed · Cited by 294
Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat
Cavaletti, G., Tredici, G., Petruccioli, M. G., Dondè, E., Tredici, P., Marmiroli, P., Minoia, C., Ronchi, A., Bayssas, M., & Griffon Etienne, G. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00300-8 · Cited by 281
Reardon, J. T., Vaisman, A., Chaney, S. G., & Sancar, A. (1999) · PubMed · Cited by 281
Gill, J. S., & Windebank, A. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1130 · Cited by 278
Self-citationAndré, T., Bensmaine, M. A., Louvet, C., François, E., Lucas, V., Desseigne, F., Beerblock, K., Bouché, O., Carola, E., Merrouche, Y., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3560 · Cited by 277
Oxaliplatin-Associated Neuropathy: A Review
Cersosimo, R. J. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e319 · Cited by 268
McDonald, E. S., Randon, K. R., Knight, A., & Windebank, A. J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.013 · Cited by 227
Self-citationScrenci, D., McKeage, M. J., Galettis, P., Hambley, T. W., Palmer, B. D., & Baguley, B. C. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1026 · Cited by 180
Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines
Arnould, S., Hennebelle, I., Canal, P., Bugat, R., & Guichard, S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00411-2 · Cited by 168
In vitro studies on the mechanisms of oxaliplatin resistance
Hector, S., Bolanowska-Higdon, W., Zdanowicz, J., Hitt, S., & Pendyala, L. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100363 · Cited by 154
Vaisman, A., Lim, S. E., Patrick, S. M., Copeland, W. C., Hinkle, D. C., Turchi, J. J., & Chaney, S. G. (1999) · Biochemistry · doi:10.1021/bi9909187 · Cited by 140
Scheeff, E. D., Briggs, J. M., & Howell, S. B. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.3.633 · Cited by 137
McDonald, E. S., & Windebank, A. J. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0468 · Cited by 135
Self-citationCisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy.
Meijer, C., de Vries, E. G. E., Marmiroli, P., Tredici, G., Frattola, L., & Cavaletti, G. (1999) · PubMed · Cited by 104
MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA
Zdraveski, Z. Z., Mello, J. A., Farinelli, C. K., Essigmann, J. M., & Marinus, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105382200 · Cited by 103
Donzelli, E., Carfì, M., Miloso, M., Strada, A., Galbiati, S., Bayssas, M., Griffon, G., Cavaletti, G., Petruccioli, M. G., & Tredici, G. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000021787.70029.ce · Cited by 95
Gourdier, I., Crabbé, L., Andréau, K., Pau, B., & Kroemer, G. (2004) · Oncogene · doi:10.1038/sj.onc.1208047 · Cited by 82
Inhibition of axonal growth from sensory neurons by excess nerve growth factor
Conti, A. M. F., Fischer, S. J., & Windebank, A. J. (1997) · Annals of Neurology · doi:10.1002/ana.410420604 · Cited by 70
Self-citationLuo, F., Wyrick, S. D., & Chaney, S. G. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050941 · Cited by 69
Müller, L. J., van der Hoop, R. G., Delft, C. M. M.-V., Gispen, W. H., & Roubos, E. W. (1990) · PubMed · Cited by 59
Alberts, S. R., Sinicrope, F. A., & Grothey, A. F. (2005) · Clinical Colorectal Cancer · doi:10.3816/ccc.2005.n.033 · Cited by 37
Cited by
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Chemotherapy‐induced neuropathy
Windebank, A. J., & Grisold, W. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00156.x · Cited by 613
Self-citationPlatinum neurotoxicity pharmacogenetics
McWhinney, S. R., Goldberg, R. M., & McLeod, H. L. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0840 · Cited by 574
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Grisold, W., Cavaletti, G., & Windebank, A. J. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos203 · Cited by 486
Self-citation
Metadata
- Authors
- Ta, L. E., Espeset, L., Podratz, J., & Windebank, A. J.
- Venue
- NeuroToxicology
- Publisher
- Elsevier BV
- Published
- 2006-12
- Volume
- 27
- Issue
- 6
- Pages
- 992-1002
- ISSN
- 0161-813X (ISSN-L)
- OpenAlex
- W2012330364
- Cited by
- 325
- References
- 36
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.